Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial

Alice B. Gottlieb, Andrew Blauvelt, Jörg C. Prinz, Philemon Papanastasiou, Rashidkhan Pathan, Judit Nyirady, Todd Fox, Charis Papavassilis

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Background: Secukinumab, a human monoclonal antibody that selectively targets interleukin-17A, is highly efficacious in the treatment of moderate-to-severe psoriasis, starting at early time points, with a sustained effect and a favorable safety profile. Methods: Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg, or placebo self-administered by prefilled syringe at baseline, weeks 1, 2, and 3, and then every four weeks from week 4 to 48. Efficacy responses (≥ 75/90/100% improvement in Psoriasis Area and Severity Index [PASI 75/90/100] and clear/almost clear skin by Investigator's Global Assessment 2011 modified version [IGA mod 2011 0/1]) were measured to week 52. Patient-reported usability of the prefilled syringe was evaluated by the Self-Injection Assessment Questionnaire to week 48. Results: The efficacy of secukinumab increased to week 16 and was maintained to week 52. With secukinumab 300 mg at week 52, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 83.5%/68.0%/47.5% and 71.5% of patients when analyzed by multiple imputation, respectively, and by 75.9%/62.1%/43.1% and 63.8% of patients when analyzed by nonresponder imputation, respectively. With secukinumab 150 mg at week 52, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 63.5%/50.3%/31.1% and 43.6% of patients when analyzed by multiple imputation, respectively, and by 61.0%/49.2%/30.5% and 42.4% of patients when analyzed by nonresponder imputation, respectively. Self-reported acceptability of the prefilled syringe was high throughout the study. The incidence of adverse events (AE) was well balanced between groups, with AEs reported in 74.4% of patients receiving secukinumab 300 mg and 77.3% of patients receiving secukinumab 150 mg. Nasopharyngitis was the most common AE across both secukinumab groups. Conclusion: Self-administration of secukinumab by prefilled syringe was associated with robust and sustained efficacy and a favorable safety profile up to week 52.

Original languageEnglish
Pages (from-to)1226-1234
Number of pages9
JournalJournal of Drugs in Dermatology
Volume15
Issue number10
StatePublished - Oct 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial'. Together they form a unique fingerprint.

Cite this